NEO
Price:
$16.39
Market Cap:
$2.10B
NeoGenomics, Inc. operates a network of cancer-focused testing laboratories in the United States, Europe, and Asia. It operates through, Clinical Services and Pharma Services segments. The company offers testing services to hospitals, reference labs, pathologists, oncologists, clinicians, pharmaceutical firms, and researchers. It provides cytogenetics testing services to study normal and abnormal chromosomes and their relationship to diseases; fluorescence in-situ hybridization testing services that focus on detecting and locating the presence or absence of specific DNA sequences and genes on chromosomes; flow cytometry testing services to measure the characteristics of cell populations; and...[Read more]
Industry
Medical - Diagnostics & Research
IPO Date
2004-03-16
Stock Exchange
NASDAQ
Ticker
NEO
According to NeoGenomics, Inc.’s latest financial reports and current stock price. The company's current ROE is -8.43%. This represents a change of 299.61% compared to the average of -2.11% of the last 4 quarters.
The mean historical ROE of NeoGenomics, Inc. over the last ten years is -2.42%. The current -8.43% ROE has changed 248.03% with respect to the historical average. Over the past ten years (40 quarters), NEO's ROE was at its highest in in the June 2021 quarter at 6.61%. The ROE was at its lowest in in the March 2022 quarter at -4.60%.
Average
-2.42%
Median
-0.58%
Minimum
-14.45%
Maximum
1.87%
Discovering the peaks and valleys of NeoGenomics, Inc. ROE, unveiling quarterly and yearly fluctuations to gain insights into the company’s financial performance and market dynamics, offering valuable data for investors and analysts alike.
Maximum Annual Increase = 1.82%
Maximum Annual ROE = 1.87%
Minimum Annual Increase = -300.15%
Minimum Annual ROE = -14.45%
Year | ROE | Change |
---|---|---|
2023 | -9.34% | -35.36% |
2022 | -14.45% | 1.82% |
2021 | -0.75% | -225.34% |
2020 | 0.60% | -61.92% |
2019 | 1.58% | 91.52% |
2018 | 0.82% | -300.15% |
2017 | -0.41% | -86.58% |
2016 | -3.07% | 188.09% |
2015 | -1.06% | -156.81% |
2014 | 1.87% | -79.99% |
The current ROE of NeoGenomics, Inc. (NEO) is greater than its 3-year, greater than its 5-year, and greater than its 10-year historical averages
3-year avg
-8.18%
5-year avg
-4.47%
10-year avg
-2.42%
NeoGenomics, Inc.’s ROE is greater than Natera, Inc. (-26.23%), less than Qiagen N.V. (2.59%), greater than Neogen Corporation (-0.75%), greater than Guardant Health, Inc. (-1240.25%), greater than CareDx, Inc (-54.41%), greater than Myriad Genetics, Inc. (-25.01%), less than Invitae Corporation (178.89%), less than Castle Biosciences, Inc. (1.47%), less than Syneos Health, Inc. (7.72%), greater than Mettler-Toledo International Inc. (-516.84%), less than ICON Public Limited Company (7.87%), less than IQVIA Holdings Inc. (21.50%), less than Charles River Laboratories International, Inc. (11.21%), less than Sotera Health Company (16.02%), greater than Olink Holding AB (publ) (-7.07%), greater than Aclaris Therapeutics, Inc. (-26.28%), greater than Twist Bioscience Corporation (-39.49%), greater than Biodesix, Inc. (-277.36%),
Company | ROE | Market cap |
---|---|---|
-26.23% | $22.08B | |
2.59% | $9.49B | |
-0.75% | $3.25B | |
-1240.25% | $4.03B | |
-54.41% | $1.24B | |
-25.01% | $1.41B | |
178.89% | $5.44M | |
1.47% | $834.90M | |
7.72% | $4.46B | |
-516.84% | $25.70B | |
7.87% | $17.69B | |
21.50% | $36.63B | |
11.21% | $10.01B | |
16.02% | $3.63B | |
-7.07% | $3.24B | |
-26.28% | $271.44M | |
-39.49% | $2.51B | |
-277.36% | $186.20M |
One of the best ways to find valuable stocks to invest in is to build a custom made screener in your Excel or Google Sheets spreadsheet. This allows you to compare thousands of companies like NeoGenomics, Inc. using the financials and key metrics that matter to you in a single view.
The easiest way to set this up is to use the Wisesheets add-on and set your spreadsheet like this:
Covering all these metrics from financial, data, dividend data, key metrics and more you can get all the data you want for over 50+ exchanges worldwide.
Get your free trial here.
The easiest way to analyze a company like NeoGenomics, Inc. or any others is to create a spreadsheet model that automatically retrieves all of the stock data you need.
Using Wisesheets you can set up a spreadsheet model like this with simple spreadsheet formulas. If you change the ticker you can get all of the data automatically updated for you.
Whether you need live data, historical price data, financials, dividend data, key metrics, analyst estimates, or anything else...Wisesheets has you covered.
What is the ROE?
How can you use the ROE?
What is NeoGenomics, Inc.'s ROE?
How is the ROE calculated for NeoGenomics, Inc. (NEO)?
What is the highest ROE for NeoGenomics, Inc. (NEO)?
What is the 3-year average ROE for NeoGenomics, Inc. (NEO)?
What is the 5-year average ROE for NeoGenomics, Inc. (NEO)?
How does the current ROE for NeoGenomics, Inc. (NEO) compare to its historical average?